Your browser doesn't support javascript.
loading
Development, behaviour and sensory processing in Marshall-Smith syndrome and Malan syndrome: phenotype comparison in two related syndromes.
Mulder, P A; van Balkom, I D C; Landlust, A M; Priolo, M; Menke, L A; Acero, I H; Alkuraya, F S; Arias, P; Bernardini, L; Bijlsma, E K; Cole, T; Coubes, C; Dapia, I; Davies, S; Di Donato, N; Elcioglu, N H; Fahrner, J A; Foster, A; González, N G; Huber, I; Iascone, M; Kaiser, A-S; Kamath, A; Kooblall, K; Lapunzina, P; Liebelt, J; Lynch, S A; Maas, S M; Mammì, C; Mathijssen, I B; McKee, S; Mirzaa, G M; Montgomery, T; Neubauer, D; Neumann, T E; Pintomalli, L; Pisanti, M A; Plomp, A S; Price, S; Salter, C; Santos-Simarro, F; Sarda, P; Schanze, D; Segovia, M; Shaw-Smith, C; Smithson, S; Suri, M; Tatton-Brown, K; Tenorio, J; Thakker, R V.
Affiliation
  • Mulder PA; Autism Team Northern-Netherlands, Jonx Department of (Youth) Mental Health and Autism, Lentis Psychiatric Institute, Groningen, Netherlands.
  • van Balkom IDC; Autism Team Northern-Netherlands, Jonx Department of (Youth) Mental Health and Autism, Lentis Psychiatric Institute, Groningen, Netherlands.
  • Landlust AM; Rob Giel Research Centre, Department of Psychiatry, University Medical Center Groningen, Groningen, Netherlands.
  • Priolo M; Autism Team Northern-Netherlands, Jonx Department of (Youth) Mental Health and Autism, Lentis Psychiatric Institute, Groningen, Netherlands.
  • Menke LA; Unità Operativa di Genetica Medica, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
  • Acero IH; Department of Paediatrics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Alkuraya FS; Genetics Unit, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Arias P; Saudi Human Genome Project, King Abdulaziz City for Science and Technology, and Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Bernardini L; Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, and CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
  • Bijlsma EK; Cytogenetics Unit, Casa Sollievo della Sofferenza Foundation, San Giovanni Rotondo, Italy.
  • Cole T; Department of Clinical Genetics, Leiden University Medical Centre, Leiden, Netherlands.
  • Coubes C; Department of Clinical Genetics, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
  • Dapia I; Département de Génétique Médicale, Hôpital Arnaud de Villeneuve, CHRU Montpellier, Montpellier, France.
  • Davies S; Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, and CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
  • Di Donato N; Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK.
  • Elcioglu NH; Institute for Clinical Genetics, TU Dresden, Dresden, Germany.
  • Fahrner JA; Department of Pediatric Genetics, Marmara University Medical School, Istanbul and Eastern Mediterranean University, Mersin, Turkey.
  • Foster A; McKusick-Nathans Institute of Genetic Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • González NG; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Huber I; Unit Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Iascone M; Sørland Hospital, Kristiansand, Norway.
  • Kaiser AS; Medical Genetics Laboratory, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Kamath A; Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.
  • Kooblall K; Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK.
  • Lapunzina P; Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Liebelt J; Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, and CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
  • Lynch SA; South Australian Clinical Genetics Services, Women's and Children's Hospital, North Adelaide, Australia.
  • Maas SM; UCD Academic Centre on Rare Diseases, School of Medicine and Medical Sciences, University College Dublin, and Clinical Genetics, Temple Street Children's University Hospital, Dublin, Ireland.
  • Mammì C; Department of Clinical Genetics, Academic Medical Center, Amsterdam, Netherlands.
  • Mathijssen IB; Unità Operativa di Genetica Medica, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
  • McKee S; Department of Clinical Genetics, Academic Medical Center, Amsterdam, Netherlands.
  • Mirzaa GM; Northern Ireland Regional Genetics Service, Belfast Health and Social Care Trust, Belfast, UK.
  • Montgomery T; Center for Integrative Brain Research, Seattle Children's Research Institute, and Division of Genetic Medicine, University of Washington School of Medicine, Seattle, WA, USA.
  • Neubauer D; Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Neumann TE; Institute of Human Genetics, University Hospital Magdeburg, Magdeburg, Germany.
  • Pintomalli L; Mitteldeutscher Praxisverbund Humangenetik, Halle, Germany.
  • Pisanti MA; Unità Operativa di Genetica Medica, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
  • Plomp AS; Medical Genetic and Laboratory Unit, "Antonio Cardarelli" Hospital, Naples, Italy.
  • Price S; Department of Clinical Genetics, Academic Medical Center, Amsterdam, Netherlands.
  • Salter C; Department of Clinical Genetics, Northampton General Hospital NHS Trust, Northampton, UK.
  • Santos-Simarro F; Wessex Clinical Genetics Service, Princess Ann Hospital, Southampton, UK.
  • Sarda P; Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, and CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
  • Schanze D; Département de Génétique Médicale, Hôpital Arnaud de Villeneuve, CHRU Montpellier, Montpellier, France.
  • Segovia M; Institute of Human Genetics, University Hospital Magdeburg, Magdeburg, Germany.
  • Shaw-Smith C; CENAGEM, Centro Nacional de Genética, Buenos Aires, Argentina.
  • Smithson S; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • Suri M; University Hospitals Bristol NHS Trust, Bristol, UK.
  • Tatton-Brown K; Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Tenorio J; Division of Genetics and Epidemiology, Institute of Cancer Research, London and South West Thames Regional Genetics Service, St. George's University Hospitals NHS Foundation Trust, London, UK.
  • Thakker RV; Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, and CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
J Intellect Disabil Res ; 64(12): 956-969, 2020 12.
Article in En | MEDLINE | ID: mdl-33034087
ABSTRACT

BACKGROUND:

Ultrarare Marshall-Smith and Malan syndromes, caused by changes of the gene nuclear factor I X (NFIX), are characterised by intellectual disability (ID) and behavioural problems, although questions remain. Here, development and behaviour are studied and compared in a cross-sectional study, and results are presented with genetic findings.

METHODS:

Behavioural phenotypes are compared of eight individuals with Marshall-Smith syndrome (three male individuals) and seven with Malan syndrome (four male individuals). Long-term follow-up assessment of cognition and adaptive behaviour was possible in three individuals with Marshall-Smith syndrome.

RESULTS:

Marshall-Smith syndrome individuals have more severe ID, less adaptive behaviour, more impaired speech and less reciprocal interaction compared with individuals with Malan syndrome. Sensory processing difficulties occur in both syndromes. Follow-up measurement of cognition and adaptive behaviour in Marshall-Smith syndrome shows different individual learning curves over time.

CONCLUSIONS:

Results show significant between and within syndrome variability. Different NFIX variants underlie distinct clinical phenotypes leading to separate entities. Cognitive, adaptive and sensory impairments are common in both syndromes and increase the risk of challenging behaviour. This study highlights the value of considering behaviour within developmental and environmental context. To improve quality of life, adaptations to environment and treatment are suggested to create a better person-environment fit.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Speech Disorders / Abnormalities, Multiple / Bone Diseases, Developmental / Craniofacial Abnormalities / Septo-Optic Dysplasia / Mental Disorders / Intellectual Disability Type of study: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: J Intellect Disabil Res Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Speech Disorders / Abnormalities, Multiple / Bone Diseases, Developmental / Craniofacial Abnormalities / Septo-Optic Dysplasia / Mental Disorders / Intellectual Disability Type of study: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: J Intellect Disabil Res Year: 2020 Document type: Article